Supplementary materials: Economic burden of early-stage non-small-cell lung cancer: an assessment of healthcare resource utilization and medical costs

These are peer-reviewed supplementary materials for the article 'Economic burden of early-stage non-small-cell lung cancer: an assessment of healthcare resource utilization and medical costs' published in the Journal of Comparative Effectiveness Research.Supplemental Table 1: ICD-O-3 codes for identification of NSCLCSupplemental Table 2: Procedure codes used to identify lung cancer-related surgerySupplemental Table 3: Pharmaceutical costs (2021 USD) during the observation period by disease stage at diagnosis and therapy typeSupplemental Table 4: Medical costs (2021 USD) during the observation period by type of surgery each patient receivedSupplemental Table 5: Healthcare resource utilization (HRU) and costs (2021 USD) during the observation period by phase of careAim: To quantify the economic burden of early-stage non-small-cell lung cancer (NSCLC) among patients with and without adjuvant therapy. Methods: All-cause and NSCLC-related healthcare resource utilization and medical costs were assessed among patients with resected stage IB–IIIA NSCLC in the SEER–Medicare database (1 January 2011–31 December 2019), from NSCLC diagnosis to death, end of continuous enrollment, or end of data availability (whichever occurred first). Results: Patients receiving adjuvant therapy had the lowest mean NSCLC-related medical costs (adjuvant [n = 1776]: $3738; neoadjuvant [n = 56]: $5793; both [n = 47]: $4818; surgery alone [n = 3478]: $4892, per-person-per-month), driven by lower NSCLC-related hospitalization rates. Conclusion: Post-surgical management of early-stage NSCLC was associated with high economic burden. Adjuvant therapy was associated with numerically lower medical costs over surgical resection alone.